Get the Stockscreener App
1.56
7.14%
-0.12
After Hours:
1.56
Lipocine Inc stock is traded at $1.56, with a volume of 395.39K.
It is down -7.14% in the last 24 hours and down -27.78% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$1.68
Open:
$1.66
24h Volume:
395.39K
Relative Volume:
0.04
Market Cap:
$12.86M
Revenue:
$2.00M
Net Income/Loss:
$-11.43M
P/E Ratio:
-0.7971
EPS:
-1.957
Net Cash Flow:
$-10.05M
1W Performance:
-9.30%
1M Performance:
-27.78%
6M Performance:
-39.06%
1Y Performance:
-49.84%
1-Day Range:
$1.48
$1.68
1-Week Range:
$1.48
$1.77
52-Week Range:
$1.48
$12.37
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
1.56 | 12.86M | 2.00M | -11.43M | -10.05M | -1.957 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-06-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Press Releases about Lipocine Inc.Common Stock (Nasdaq:LPCN) - FinancialContent
Lipocine Inc. (LPCN) stock price, news, quote and history - Yahoo Finance Singapore
Here's Why You Should Add LPCN Stock to Your Portfolio Now - TradingView
Here's Why You Should Add LPCN Stock to Your Portfolio Now - Zacks Investment Research
Here's Why You Should Add LPCN Stock to Your Portfolio Now - TradingView
Lipocine LPCN Rallies As BLOOM Phase 3 Trial Kicks Off - StocksToTrade
Lipocine (LPCN) Advances BLOOM Trial As Traders Eye Cash Runway - Timothy Sykes
Lipocine Shares Surge 30% After Health Canada Clears Oral Testosterone Drug - BigGo Finance
LPCN Stock Jumps As BLOOM Phase 3 Trial Kicks Off - StocksToTrade
Lipocine Surges After Canada Approves TLANDO - Quiver Quantitative
Why Is Lipocine Stock Soaring Today?Lipocine (NASDAQ:LPCN) - Benzinga
Lipocine Health Canada Approval Clears TLANDO for Canadian Testosterone Replacement Market - Yahoo Finance
Lipocine stock surges 30% on Health Canada drug approval - Yahoo Finance
LPCN Stock Pops As BLOOM Phase 3 Trial Kicks Off - www.timothysykes.com
LPCN Stock Pops As BLOOM Phase 3 Trial Kicks Off - Timothy Sykes
Hecla Mining, XPO, Lipocine - TradingView
Lipocine stock surges 30% on Health Canada drug approval - Investing.com
LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today - Stocktwits
LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today - Yahoo Finance
LPCN Stock Jumps As BLOOM Phase 3 Trial Kicks Off - StocksToTrade
Health Canada approves Lipocine’s testosterone therapy drug By Investing.com - Investing.com India
Health Canada approves Lipocine's oral testosterone drug TLANDO - StreetInsider
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy - PR Newswire
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy - Nasdaq
Lipocine (LPCN) Jumps As BLOOM Phase 3 Trial Kicks Off - Timothy Sykes
Lipocine (LPCN) Jumps As BLOOM Phase 3 Trial Kicks Off - Timothy Sykes
LPCN Jumps As Lipocine Launches Phase 3 BLOOM Trial - StocksToTrade
Health Canada approves Tlando oral testosterone therapy from Lipocine - StreetInsider
Lipocine Inc. (LPCN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Lipocine Inc. (LPCN) stock price, news, quote and history - Yahoo Finance UK
Form 4 Lipocine Inc For: 1 October By Investing.com - Investing.com Nigeria
Lipocine director John Higuchi buys $55,042 in company stock By Investing.com - Investing.com South Africa
Lipocine director John Higuchi buys $55,042 in company stock By Investing.com - Investing.com Nigeria
Lipocine director John Higuchi buys $55,042 in company stock - Investing.com
Lipocine director John Higuchi buys $27,131 in company stock - Investing.com
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Lipocine stock price target maintained at $4 by H.C. Wainwright - Investing.com
Lipocine (NASDAQ: LPCN) shares slides from New York investor conference - Stock Titan
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression - PR Newswire
Lipocine launches BLOOM Phase 3 study of LPCN 1154 for PPD; plans ~120 patients, expects $1M/mo cash use - TradingView
Form 8K Lipocine Inc For: 11 September By Investing.com - Investing.com Australia
Form 8K Lipocine Inc For: 11 September By Investing.com - Investing.com Nigeria
Lipocine Cuts ATM Sales Agent Fee to Up to 3.0% - minichart.com.sg
Form 8K Lipocine Inc For: 11 September By Investing.com - Investing.com Canada
Form 8K Lipocine Inc For: 11 September By Investing.com - Investing.com South Africa
Lipocine updates sales agent fee agreement with A.G.P./Alliance Global Partners - Investing.com India
Lipocine updates sales agent fee agreement with A.G.P./Alliance Global Partners - Investing.com Canada
Lipocine updates sales agent fee agreement with A.G.P./Alliance Global Partners - Investing.com
Lipocine Updates Sales Agreement Fee Structure with A.G.P. - TipRanks
Lipocine (LPCN) sets sales agent commissions at up to 3% - Stock Titan
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lipocine Inc Stock (LPCN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Higuchi John W. | Director |
Sep 29 '26 |
Buy |
2.15 |
9,037 |
19,430 |
225,395 |
| Higuchi John W. | Director |
Sep 28 '26 |
Buy |
2.16 |
12,561 |
27,132 |
216,358 |
| Higuchi John W. | Director |
Apr 07 '26 |
Buy |
2.03 |
40,000 |
81,200 |
203,797 |
| Higuchi John W. | Director |
Apr 06 '26 |
Buy |
2.05 |
123,000 |
252,150 |
163,797 |
| Patel Mahesh V. | Chief Executive Officer |
Apr 06 '26 |
Buy |
2.03 |
25,000 |
50,750 |
160,679 |
| Patel Mahesh V. | Chief Executive Officer |
Apr 02 '26 |
Buy |
2.02 |
25,000 |
50,500 |
135,679 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):